Kronisk bihulebetændelse og type 2-sygdom

Kasper Aanæs; Mikkel Christian Alanin; Elisabeth Arndal; Vibeke Backer; Eva Kirkegaard Kiær; Niclas Rubek; Henrik Bredahl Sørensen; Christian von Buchwald

Kronisk bihulebetændelse og type 2-sygdom

Translated title of the contribution: Chronic rhinosinusitisand type 2 disease

Kasper Aanæs, Mikkel Christian Alanin, Elisabeth Arndal, Vibeke Backer, Eva Kirkegaard Kiær, Niclas Rubek, Henrik Bredahl Sørensen, Christian von Buchwald

1 Citation (Scopus)

Abstract

Diseases of the upper and lower airways are commonly described as global airway disease, which shares basic inflammatory mechanisms, and airway comobidity is frequently found. The prevalence of chronic rhinosinusitis (CRS) is 5-12%, characterised as CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP). Inflammation in CRSwNP is often type 2, whereas CRSsNP often involves non-type 2. New monoclonal antibodies towards type-2 inflammation have been launched internationally to treat refractory severe CRSwNP, with effect on polyps, congestions and smell, as well as quality of life. This review gives a summary of the current treatment modalities.

Translated title of the contribution	Chronic rhinosinusitisand type 2 disease
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	184
Issue number	10
ISSN	0041-5782
Publication status	Published - 7 Mar 2022

Cite this

@article{703296894d1a408f98dec11d603d66fe,

title = "Kronisk bihulebet{\ae}ndelse og type 2-sygdom",

abstract = "Diseases of the upper and lower airways are commonly described as global airway disease, which shares basic inflammatory mechanisms, and airway comobidity is frequently found. The prevalence of chronic rhinosinusitis (CRS) is 5-12\%, characterised as CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP). Inflammation in CRSwNP is often type 2, whereas CRSsNP often involves non-type 2. New monoclonal antibodies towards type-2 inflammation have been launched internationally to treat refractory severe CRSwNP, with effect on polyps, congestions and smell, as well as quality of life. This review gives a summary of the current treatment modalities.",

keywords = "Chronic Disease, Humans, Nasal Polyps/complications, Quality of Life, Rhinitis/complications, Sinusitis/complications",

author = "Kasper Aan{\ae}s and Alanin, \{Mikkel Christian\} and Elisabeth Arndal and Vibeke Backer and Ki{\ae}r, \{Eva Kirkegaard\} and Niclas Rubek and S{\o}rensen, \{Henrik Bredahl\} and \{von Buchwald\}, Christian",

year = "2022",

month = mar,

day = "7",

language = "Dansk",

volume = "184",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "10",

}

TY - JOUR

T1 - Kronisk bihulebetændelse og type 2-sygdom

AU - Aanæs, Kasper

AU - Alanin, Mikkel Christian

AU - Arndal, Elisabeth

AU - Backer, Vibeke

AU - Kiær, Eva Kirkegaard

AU - Rubek, Niclas

AU - Sørensen, Henrik Bredahl

AU - von Buchwald, Christian

PY - 2022/3/7

Y1 - 2022/3/7

N2 - Diseases of the upper and lower airways are commonly described as global airway disease, which shares basic inflammatory mechanisms, and airway comobidity is frequently found. The prevalence of chronic rhinosinusitis (CRS) is 5-12%, characterised as CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP). Inflammation in CRSwNP is often type 2, whereas CRSsNP often involves non-type 2. New monoclonal antibodies towards type-2 inflammation have been launched internationally to treat refractory severe CRSwNP, with effect on polyps, congestions and smell, as well as quality of life. This review gives a summary of the current treatment modalities.

AB - Diseases of the upper and lower airways are commonly described as global airway disease, which shares basic inflammatory mechanisms, and airway comobidity is frequently found. The prevalence of chronic rhinosinusitis (CRS) is 5-12%, characterised as CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP). Inflammation in CRSwNP is often type 2, whereas CRSsNP often involves non-type 2. New monoclonal antibodies towards type-2 inflammation have been launched internationally to treat refractory severe CRSwNP, with effect on polyps, congestions and smell, as well as quality of life. This review gives a summary of the current treatment modalities.

KW - Chronic Disease

KW - Humans

KW - Nasal Polyps/complications

KW - Quality of Life

KW - Rhinitis/complications

KW - Sinusitis/complications

UR - https://www.scopus.com/pages/publications/85126844414

M3 - Review

C2 - 35315753

SN - 0041-5782

VL - 184

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 10

ER -

Kronisk bihulebetændelse og type 2-sygdom

Abstract

Other files and links

Fingerprint

Cite this